4/A: AN2 Therapeutics CFO Lucy Day Reports Amended Vesting Schedule for Restricted Stock Units

Lucy Day, CFO of AN2 Therapeutics, filed an amendment to a previous Form 4, detailing the vesting schedule for her restricted stock units.

Summary

• Lucy Day, the Chief Financial Officer of AN2 Therapeutics, filed an amended Form 4 with the SEC.
• The amendment pertains to a previous filing on March 18, 2024, and clarifies the vesting schedule for restricted stock units.
• 27,500 shares were acquired on March 15, 2024, at a price of $0.
• The vesting schedule is 1/4th of the shares vesting annually over four years from January 1, 2024, subject to continuous service.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions and vesting schedules. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as officers and directors, in their company's stock. This allows the public to see if insiders are buying or selling shares, which can provide insights into their confidence in the company's future prospects.

Stakeholder Impact

• Shareholders may be interested in the vesting schedule of executive compensation.

Key Dates